Mumbai: In a recent press release pharma major Lupin announced the receipt of the Establishment Inspection Report (EIR) on the completion of an inspection by the US FDA (United States Food & Drug Administration) at its facility in Tarapur, Maharashtra. The inspection conducted between August 27 and August 31, 2018, concluded with one inspectional observation.
Founded in 1992, the Tarapur facility is a state-of-the-art unit for manufacturing Active Pharmaceuticals Ingredients (API), both fermentation-based and synthetic.
Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, “For Lupin, meeting and exceeding global quality and procedural standards has always been paramount. We are committed to upholding the highest levels of quality and compliance standards across all our facilities.”